aortoseal A minimally invasive and durable endograft fastening solution for Abdominal Aortic Aneurysm (AAA)
- Coordinator
- Endoron Medical Ltd., Israel
- Runs
- 1 February 2023 to 31 July 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €6.0m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190131747
What the project is doing
In the project's own words, from its summary on CORDIS.
Abdominal aortic aneurysm (AAA) is a focal enlargement of the abdominal aorta below the renal arteries and is found in up to 4 million patients globally each year. If left untreated it can be fatal, so it is imperative to provide early, prophylactic treatment before a rupture occurs. The available treatment options are far from optimal: open surgery is a durable, life-long, but high-risk solution. The alternative, EVAR, has lower immediate risks, but is a shorter-term solution and requires continual monitoring and secondary interventions.
We have developed Aortoseal, a fixation and sealing implant for endovascular aneurysm repair that combines the best of both worlds: the stability of an open, sutured repair and the safety and low-risk delivery of EVAR. Aortoseal will reduce the need for open surgery, the need for secondary procedures and time in the hospital, all leading to improved patient outcomes and projected healthcare savings over a 10 year period of ~9 bn across the EU.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Endoron Medical Ltd. | Kfar Saba | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI